+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P11523(CALCA Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The CALCA antibody targets calcitonin gene-related peptide (CGRP), a neuropeptide encoded by the *CALCA* gene. CGRP exists in two forms: α-CGRP, primarily expressed in sensory neurons, and β-CGRP, found in enteric nerves. Both isoforms bind to the CGRP receptor, mediating diverse physiological roles, including vasodilation, nociception, and inflammation modulation. α-CGRP is notably implicated in migraine pathophysiology, driving peripheral and central sensitization.

CALCA antibodies are crucial tools in research and diagnostics. They enable detection of CGRP in tissues and fluids, aiding studies on neuronal signaling, pain mechanisms, and inflammatory conditions. In clinical contexts, anti-CGRP monoclonal antibodies (e.g., erenumab, fremanezumab) have emerged as targeted therapies for chronic migraine, blocking CGRP or its receptor to prevent pain transmission.

Commercial CALCA antibodies are typically developed using synthetic peptides or recombinant CGRP as immunogens. Validation includes Western blot, immunohistochemistry, and ELISA to ensure specificity for α- or β-CGRP isoforms. Challenges include cross-reactivity due to structural similarities between CGRP and related peptides like amylin. Ongoing research explores CALCA antibody applications in cancer (CGRP’s role in angiogenesis) and cardiovascular diseases (vasoregulatory effects). Understanding CGRP’s dual pro- and anti-inflammatory roles remains a focus, highlighting the antibody’s versatility in unraveling complex biological pathways.